Study guide

Diabetes diagnosis and ongoing care

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Diabetes diagnosis and ongoing care

Key Takeaways Explain This Topic AI

Confirm abnormal results in asymptomatic patients using the diagnostic pathway.

HbA1c can be unreliable with altered red-cell survival or recent transfusion.

PBS eligibility and clinical suitability are related but separate prescribing questions.

Last updated: October 2026

Type 1 & 2 Diabetes, Diabetic Ketoacidosis & Hyperglycaemic Hyperosmolar State

Diabetes mellitus is one of the most prevalent chronic health conditions in Australia, affecting over 1.3 million registered individuals. Mastery of diagnostic thresholds, Australian Pharmaceutical Benefits Scheme (PBS) stepped pharmacotherapy, immediate protocols for acute glycaemic emergencies (DKA and HHS), and systematic microvascular/macrovascular surveillance is foundational for clinical practice and medical licensing assessments.

Diagnostic Criteria for Diabetes Mellitus

According to the Australian Diabetes Society (ADS) and World Health Organization (WHO) guidelines, diabetes mellitus is established through venous plasma glucose or standardised glycated haemoglobin (HbA1c) assays.

Diagnostic Thresholds Matrix

Fasting Plasma Glucose (FPG) : Normal: < 6.1 mmol/L < 6.1\text{ mmol/L} < 6.1 mmol/L ; Impaired Fasting Glycaemia (IFG) / Impaired Glucose Tolerance (IGT): 6.1 − 6.9 mmol/L 6.1 - 6.9\text{ mmol/L} 6.1 − 6.9 mmol/L (IFG); Diabetes Mellitus: ≥ 7.0 mmol/L \ge 7.0\text{ mmol/L} ≥ 7.0 mmol/L

2-hour 75g Oral Glucose Tolerance Test (OGTT) : Normal: < 7.8 mmol/L < 7.8\text{ mmol/L} < 7.8 mmol/L ; Impaired Fasting Glycaemia (IFG) / Impaired Glucose Tolerance (IGT): 7.8 − 11.0 mmol/L 7.8 - 11.0\text{ mmol/L} 7.8 − 11.0 mmol/L (IGT); Diabetes Mellitus: ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L

Glycated Haemoglobin (HbA1c) : Normal: < 6.0 % < 6.0\% < 6.0% ( < 42 mmol/mol < 42\text{ mmol/mol} < 42 mmol/mol ); Impaired Fasting Glycaemia (IFG) / Impaired Glucose Tolerance (IGT): 6.0 − 6.4 % 6.0 - 6.4\% 6.0 − 6.4% ( 42 − 47 mmol/mol 42 - 47\text{ mmol/mol} 42 − 47 mmol/mol ) (Prediabetes); Diabetes Mellitus: ≥ 6.5 % \ge 6.5\% ≥ 6.5% ( ≥ 48 mmol/mol \ge 48\text{ mmol/mol} ≥ 48 mmol/mol )

Random Plasma Glucose : Normal: < 7.8 mmol/L < 7.8\text{ mmol/L} < 7.8 mmol/L ; Impaired Fasting Glycaemia (IFG) / Impaired Glucose Tolerance (IGT): —; Diabetes Mellitus: ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L with classic symptoms

Clinical Rules for Confirmation

Symptomatic Patients: A single elevated value in the diabetic range in an individual with unequivocal osmotic symptoms (polyuria, polydipsia, unexplained weight loss, lethargy) confirms diabetes mellitus without requiring repeat testing.

Asymptomatic Patients: A single elevated result never confirms diabetes . A second confirmatory venous test must be performed on a separate day (preferably using the same assay type). If two different tests (e.g. FPG and HbA1c) are discordant, the test that exceeded the diagnostic cutoff should be repeated.

When HbA1c Is Unreliable: Conditions altering red blood cell turnover invalidate HbA1c. In patients with haemoglobinopathies (e.g. thalassaemias, sickle cell disease), severe haemolytic anaemia, recent blood transfusion ( < 3 months < 3\text{ months} < 3 months ), end-stage kidney disease on haemodialysis, or pregnancy (gestational diabetes), diagnosis must rely strictly on venous plasma glucose criteria (FPG or 75g OGTT).

Stepped Pharmacotherapy for Type 2 Diabetes in Australia

The Australian Diabetes Society and Royal Australian College of General Practitioners (RACGP) recommend target-driven, stepped pharmacotherapy following lifestyle optimization (medical nutrition therapy and structured physical activity).

Pharmacotherapy Classes and Clinical Characteristics

Biguanides : Examples: Metformin; Mechanism of Action: Activates hepatic AMP-activated protein kinase (AMPK), inhibiting gluconeogenesis and enhancing peripheral insulin sensitivity; Clinical Benefits & Target Populations: First-line choice in all newly diagnosed T2DM; weight neutral; low hypoglycaemia risk; cardiovascular safety; Adverse Effects & Safety Caveats: Gastrointestinal upset (nausea, diarrhoea; mitigate by slow titration); vitamin B12 malabsorption; lactic acidosis risk. Renal cutoff: reduce dose if eGFR < 45 mL/min/1.73 m 2 < 45\text{ mL/min/1.73 m}^2 < 45 mL/min/1.73 m 2 ; cease if eGFR < 30 mL/min/1.73 m 2 < 30\text{ mL/min/1.73 m}^2 < 30 mL/min/1.73 m 2

SGLT2 inhibitors: Kidney thresholds depend on the medicine and indication. Check current Australian product information and PBS restrictions; thresholds for heart failure/CKD use differ from glycaemic efficacy. Discuss genital infection, volume depletion, ketoacidosis and sick-day interruption.

GLP-1 Receptor Agonists : Examples: Semaglutide, Dulaglutide; Mechanism of Action: Incretin mimetic: stimulates glucose-dependent insulin secretion, suppresses postprandial glucagon, slows gastric emptying; Clinical Benefits & Target Populations: Significant weight loss ( 5 − 15 % 5-15\% 5 − 15% ), major adverse cardiovascular event (MACE) reduction in established ASCVD; Adverse Effects & Safety Caveats: Nausea, vomiting, diarrhoea, gastroparesis; rare acute pancreatitis; check the specific Australian product information for contraindications and precautions; US thyroid-tumour label restrictions must not be presented as a universal Australian class contraindication

DPP-4 Inhibitors : Examples: Sitagliptin, Linagliptin; Mechanism of Action: Inhibits dipeptidyl peptidase-4 enzyme, prolonging endogenous incretin hormone (GLP-1 and GIP) half-life; Clinical Benefits & Target Populations: Weight neutral; excellent tolerability; low hypoglycaemia risk. Linagliptin requires no renal dose adjustment (biliary excretion); Adverse Effects & Safety Caveats: Nasopharyngitis, rare acute pancreatitis, joint pain. Do not combine with GLP-1 receptor agonists (no additive efficacy)

Sulfonylureas : Examples: Gliclazide, Glimepiride; Mechanism of Action: Binds to K ATP \text{K}_{\text{ATP}} K ATP ​ channel on pancreatic β \beta β -cell membranes, stimulating insulin release independently of glucose; Clinical Benefits & Target Populations: Rapid glycaemic lowering; inexpensive oral option; Adverse Effects & Safety Caveats: Hypoglycaemia (especially in elderly and renal impairment), weight gain. Gliclazide modified-release (MR) has lower hypoglycaemic risk than older agents (glibenclamide)

Basal Insulins : Examples: Insulin glargine, Insulin degludec; Mechanism of Action: Long-acting human insulin analogues providing peakless, steady 24-hour basal insulinisation; Clinical Benefits & Target Populations: Unrestricted efficacy; indicated when multi-drug oral therapy fails to achieve glycaemic targets; Adverse Effects & Safety Caveats: Hypoglycaemia, weight gain, injection site lipodystrophy. Commenced at 10 units 10\text{ units} 10 units or 0.1 − 0.2 units/kg 0.1-0.2\text{ units/kg} 0.1 − 0.2 units/kg subcutaneously at bedtime

PBS Prescribing Rules in Australia

Metformin is the default first-line agent.

PBS access: Drug subsidy depends on the current item’s indication and restriction. Do not equate clinical guideline suitability with automatic PBS eligibility, or apply a single HbA1c threshold to every GLP1/SGLT2 indication.

Fixed-dose combination tablets (e.g. metformin + empagliflozin, metformin + sitagliptin) streamline pill burden and improve long-term adherence.

Primary references (checked 7 October 2026): 2024 hyperglycaemic-crisis consensus .

Australian Ozempic product information gives medicine-specific indications, contraindications and precautions.